These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Kang SS; Wong PW; Malinow MR Annu Rev Nutr; 1992; 12():279-98. PubMed ID: 1503807 [No Abstract] [Full Text] [Related]
4. Causes and consequences of hyperhomocyst(e)inemia. Pietrzik K; Brönstrup A Int J Vitam Nutr Res; 1997; 67(5):389-95. PubMed ID: 9350483 [TBL] [Abstract][Full Text] [Related]
13. Intermittent encephalopathy, reversible nerve conduction slowing, and MRI evidence of cerebral white matter disease in methylenetetrahydrofolate reductase deficiency. Walk D; Kang SS; Horwitz A Neurology; 1994 Feb; 44(2):344-7. PubMed ID: 8309589 [TBL] [Abstract][Full Text] [Related]
14. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Weger M; Stanger O; Deutschmann H; Temmel W; Renner W; Schmut O; Semmelrock J; Haas A Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):286-90. PubMed ID: 11981642 [TBL] [Abstract][Full Text] [Related]
15. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine. Ducloux D; Fournier V; Rebibou JM; Bresson-Vautrin C; Gibey R; Chalopin JM Clin Nephrol; 1998 Apr; 49(4):232-5. PubMed ID: 9582553 [TBL] [Abstract][Full Text] [Related]
16. Nutritional supplementation in the management of hyperhomocyst(e)inemia: an update. Shaikh A Indian Heart J; 2000; 52(7 Suppl):S31-34. PubMed ID: 11339438 [No Abstract] [Full Text] [Related]
17. Critical points for determining moderate hyperhomocyst(e)inaemia. Kang SS Eur J Clin Invest; 1995 Nov; 25(11):806-8. PubMed ID: 8582444 [No Abstract] [Full Text] [Related]